Drug intelligence / Profile preview

lactobacillus acidophilus + bifidobacterium lactis + bifidobacterium longum + bifidobacterium bifidum

Development stage
Unknown
Lead developer
Ardeypharm
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

This product is a **combination probiotic formulation** containing the bacterial strains *Lactobacillus acidophilus*, *Bifidobacterium lactis*, *Bifidobacterium longum*, and *Bifidobacterium bifidum*. These strains are naturally occurring, Gram-positive, lactic acid-producing bacteria commonly found in the human gastrointestinal tract. They are administered as **probiotics** to support intestinal flora balance, improve digestive health, and modulate immune responses. *L. acidophilus* and species of *Bifidobacterium* play roles in fermenting carbohydrates, producing lactic acid, reducing intestinal inflammation, and regulating immune signaling pathways such as NF-κB and MAPK. They have been investigated for benefits in **irritable bowel syndrome (IBS)**, inflammatory bowel disease (IBD), supporting barrier function, and other digestive disturbances. The mechanism includes modulation of gut microbiota, enhancement of mucosal integrity, production of bioactive metabolites, and anti-inflammatory signaling via increased toll-like receptor 2 (TLR2) and decreased cytokine production[1][3][5][6].

02

Targets

TLR2 (Toll-like Receptor 2)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on lactobacillus acidophilus + bifidobacterium lactis + bifidobacterium longum + bifidobacterium bifidum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus acidophilus + bifidobacterium lactis + bifidobacterium longum + bifidobacterium bifidum.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call